- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01836328
Conversion From Parenteral to Oral Methadone. (RATIOMTD)
Prospective Randomized Simple Blinded Study Comparing Two Conversion Ratios From Parenteral to Oral Methadone in Patients With Cancer Pain.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVE: To compare the different ratios of conversion from MTD VP to MTD PO. To verify the presence of lower toxicity in the ratio 1:1.2 against 1:2 while still maintaining a good control of pain in patients with advanced cancer that are hospitalized in different palliative care units.
METHODOLOGY: Prospective randomized single blind study in patients with cancer pain treated with parenteral MTD and that would move into MTD oral provided there is good control of pain. The patients will be randomly split into two groups: (Group A = ratio 1:1.2 and Group B=ratio 1:2). Patients will be evaluated during the two days before the switch is applied, the day of the change and during the 3 days post-ROP. The patients who display significant toxicity and/or bad analgesic control within the first 72 hours post-ROP will be considered negative cases. The size of the sample required will include 44 patients distributed in balanced groups in order to obtain a size effect of 45% and a statistical power of 80%. The significance level will be 0.05 for two tails.
STATISTIC ANALYSIS: By means of Chi-squared to compare the proportion of Opioid Rotation (OR) failure in both groups of study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Lleida, Spain, 25198
- Hospital Arnau de Vilanova
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
-
Barcelona
-
L'hospitalet de Llobregat, Barcelona, Spain, 08907
- Institut Català D'Ncologia. Hospital Duran Y Reynals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of advanced disease of any type of malignancy;
- >18 years old at the time of inclusion;
- for inclusion in the screening phase, the patient is a candidate to pass parenteral methadone to oral methadone (MTD) following to the physician criteria.
for inclusion in the assessment phase should follow: presence of cancer pain controlled with no significant toxicity with MTD VP for 48h. Be considered controlled pain and absence of significant toxicity due to MTD, as the definitions given in the general protocol;
e) signing the informed consent form.
Exclusion Criteria:
- impairment cognitive status that interferes with the assessment;
- diagnosis of psychiatric disorders at the time of recruitment that alters the ability to evaluate;
presence of side effects due to chemotherapy and / or radiotherapy prior to the change of route of administration, taking into account the following two criteria:
- For patients on a protocol of successive cycles of chemotherapy (no change in chemotherapy regimen), having presented side effects due to chemotherapy in the 15 days prior to the change of route of administration as clinically and following the recommendations of the 2011 4th ed Oncomecum of the Spanish Society of Medical Oncology and deemed that may interfere with the assessment of the primary endpoint.
- For patients starting a new protocol of chemotherapy or radiotherapy, have submitted side effects due to such treatment in the 28 days prior to the change of route of administration based on clinical judgment and following the recommendations of the Oncomecum 2011 4th ed. of the Spanish Society of Medical Oncology and deemed that may interfere with the assessment of the primary endpoint.
- invasive anesthesic techniques have been made during the 3 days before changing to oral parenteral;
- patients at agony.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Parenteral /oral methadone ratio 1:2
Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase. Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient. Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization. INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days. |
See "arm/group descriptions"
Other Names:
|
EXPERIMENTAL: Parenteral /oral methadone ratio 1:1.2
Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase. Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient. Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization. INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days. |
See "arm/group descriptions"
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of intoxicated patients in each groups
Time Frame: at 3 days after opioid rotation to Oral Methadone
|
at 3 days after opioid rotation to Oral Methadone
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Parenteral/oral MTD final ratio in patients considered as "failure"
Time Frame: One week after the change from pareteral to oral MTD
|
One week after the change from pareteral to oral MTD
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: JESÚS GONZÁLEZ-BARBOTEO, MD, INSTITUT CATALÀ D'ONCOLOGIA. HOSPITAL DURAN I REYNALS
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RATIOMTD-010810
- 2010-024092-39 (EUDRACT_NUMBER)
- EC10-133 (OTHER_GRANT: Spanish Ministry of Health 2010 Non-Commercial Research Call)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Parenteral /oral methadone ratio 1:2
-
Gangnam Severance HospitalCompletedBlood Loss, SurgicalKorea, Republic of
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
Samsung Medical CenterCompletedUterine Myoma | Ovarian Cyst | Laparoscopic Gynecologic SurgeryKorea, Republic of
-
Samsung Medical CenterCompletedLung Cancer | One Lung Ventilation | Gas Exchange | Inverse-ratio VentilationKorea, Republic of
-
Yonsei UniversityCompletedGeneral Anesthesia Using Endotracheal IntubationKorea, Republic of
-
Boehringer IngelheimRecruitingPatients With Small Cell Lung Carcinoma and Other NeoplasmsUnited States, Spain, Germany, Japan
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... and other collaboratorsCompleted
-
Gachon University Gil Medical CenterCompletedHypoxiaKorea, Republic of
-
Minia UniversityCompleted
-
Seoul National University HospitalCompletedProstatic Neoplasm | Urinary Bladder NeoplasmKorea, Republic of